Losartan Potassium
Product Images NDC 53002-6643

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 53002-6643). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530026643)

Losartan Potassium 50 mg tablets label by RPK Pharmaceuticals, Inc. The label states 'Take 1 tablet daily as directed' and shows a 100 tablets count. It includes dosage instructions, prescribing information, barcode, lot number, expiration date, and placeholder text for clinic and prescriber names.*

FDA Label Image

Figure 1 (Losartan Fig1)

A line chart comparing the percentage of patients with a primary endpoint over study months between Atenolol (dotted line) and Losartan Potassium Tablets (solid line). The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of patients up to 16%. The chart indicates an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Figure 2 (Losartan Fig2)

A line graph comparing the percentage of patients experiencing fatal or non-fatal stroke over study months for Atenolol and Losartan Potassium Tablets. Atenolol is represented by a dotted line, and Losartan Potassium Tablets by a solid line, showing lower stroke incidence over time for Losartan. The graph notes an adjusted risk reduction of 25% with statistical significance (p = 0.001).*

FDA Label Image

Figure 3 (Losartan Fig3)

A forest plot figure titled 'Figure 3 Primary Endpoint Events within Demographic Subgroups' comparing Losartan potassium tablets and Atenolol for primary composite and stroke (fatal/non-fatal) event rates across patient subgroups. The chart shows hazard ratios with 95% confidence intervals for age, gender, race, ischemic heart disease (ISH), diabetes, and history of cardiovascular disease (CVD), indicating comparative risk favoring either Losartan or Atenolol.*

FDA Label Image

Figure 4 (Losartan Fig4)

A line graph comparing the percentage of patients with an event over 48 months for Losartan Potassium Tablets versus Placebo. The graph shows a lower percentage of patients with events in the Losartan Potassium group, indicating a risk reduction of 16.1% with a p-value of 0.022.*

FDA Label Image

Losartan-str.jpg (Losartan Str)

Chemical structure of Losartan Potassium, depicting its molecular arrangement including the distinctive biphenyl and tetrazole groups with a potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.